Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka Mepsevii

Vestronidase alfa — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Vestronidase alfa (also known as Mepsevii) is a peptide catalogued under Enzymes (MPS VII). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Vestronidase alfa?

Vestronidase alfa (brand name Mepsevii) is a recombinant human beta-glucuronidase (rhGUS). It is an FDA-approved enzyme replacement therapy, granted approval in November 2017 for mucopolysaccharidosis type VII (MPS VII, Sly syndrome), an ultra-rare inherited lysosomal storage disorder.

It is a prescription biologic given by intravenous infusion and carries a boxed warning for anaphylaxis.

Because MPS VII is extremely rare, the clinical evidence base is small: it centers on a pivotal phase 3 Blind Start randomized trial with a limited number of patients, supported by early-phase and long-term extension data.

How does Vestronidase alfa work?

MPS VII is caused by deficient lysosomal beta-glucuronidase, leading to accumulation of glycosaminoglycans (GAGs) in tissues throughout the body.

Vestronidase alfa supplies functional enzyme that is taken up into lysosomes to break down accumulated GAGs, reducing substrate storage.

What does the research say about Vestronidase alfa?

  • In the phase 3 Blind Start trial, vestronidase alfa reduced urinary glycosaminoglycan excretion, a biomarker of MPS VII substrate burden. [1]
  • Individual patients showed improvements in measures such as walking and pulmonary function, though responses were heterogeneous across the small, varied population. [4]
  • Long-term treatment sustained reductions in urinary GAG with a safety profile consistent with earlier data. [2]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease — Harmatz P et al., Molecular Genetics and Metabolism 2018. (Phase 3 randomized controlled trial)
  • [2] The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII — Wang RY et al., Molecular Genetics and Metabolism 2020. (Long-term phase 3 extension study)
  • [3] Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII — Jones S et al., Molecular Genetics and Metabolism Reports 2021. (Phase 1/2 open-label study)
  • [4] Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population — Haller C et al., JIMD Reports 2019. (Post hoc individual-response analysis)
  • [5] Vestronidase Alfa: A Review in Mucopolysaccharidosis VII — McCafferty EH et al., BioDrugs 2019. (Drug review)
  • [6] Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII — Giugliani R et al., Orphanet Journal of Rare Diseases 2024. (Multicenter observational study)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical use it is administered by a healthcare professional as an intravenous infusion, typically once every two weeks, with the dose calculated by body weight.

This is context only, not a recommendation; the regimen, premedication, and monitoring are determined by the treating specialist per the approved label.

Side effects & safety profile

Vestronidase alfa carries a boxed warning for anaphylaxis, which has occurred during infusions; patients are monitored and infusions are given where such reactions can be managed, often with premedication.

Other adverse effects include infusion-associated reactions such as fever, itching, rash, and swelling.

As with other enzyme replacement therapies, anti-drug antibodies can develop; critically, the enzyme does not cross the blood-brain barrier, so it does not treat the central nervous system manifestations of MPS VII.

Stacking & combinations

It is a disease-specific enzyme replacement therapy used alone and is not intended to be combined or stacked with other peptides or performance compounds.

Finding Vestronidase alfa vendors

Finding Vestronidase alfa vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

It is FDA-approved (November 2017) as an enzyme replacement therapy for mucopolysaccharidosis type VII (MPS VII, Sly syndrome), an ultra-rare inherited lysosomal storage disorder.

References

  1. [1] A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease — Harmatz P et al., Molecular Genetics and Metabolism 2018. PMID: 29478819. View sourceStudy: Phase 3 randomized controlled trialVestronidase alfa reduced urinary glycosaminoglycan excretion in patients with MPS VII in a novel Blind Start design.
  2. [2] The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII — Wang RY et al., Molecular Genetics and Metabolism 2020. PMID: 32063397. View sourceStudy: Long-term phase 3 extension studyExtended treatment maintained reductions in urinary GAG with a consistent safety profile.
  3. [3] Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII — Jones S et al., Molecular Genetics and Metabolism Reports 2021. PMID: 34136357. View sourceStudy: Phase 1/2 open-label studyEarly-phase data supported the biochemical activity and tolerability of vestronidase alfa in MPS VII.
  4. [4] Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population — Haller C et al., JIMD Reports 2019. PMID: 31497482. View sourceStudy: Post hoc individual-response analysisIndividualized assessment showed treatment responses across a clinically heterogeneous MPS VII population.
  5. [5] Vestronidase Alfa: A Review in Mucopolysaccharidosis VII — McCafferty EH et al., BioDrugs 2019. PMID: 30848434. View sourceStudy: Drug reviewSummarizes the efficacy and safety profile of vestronidase alfa as approved therapy for MPS VII.
  6. [6] Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII — Giugliani R et al., Orphanet Journal of Rare Diseases 2024. PMID: 38715031. View sourceStudy: Multicenter observational studyReal-world data described disease characteristics and supported the effectiveness and safety of vestronidase alfa in MPS VII.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.